European regulators have approved a label update for AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) to include a dosing regimen specifically to treat hyperkalaemia in patients with end-stage renal disease on stable haemodialysis.
The decision rides on the back of findings from the Phase IIIb DIALIZE trial, which AZ says is the first-ever randomised, placebo-controlled trial to evaluate a potassium binder in patients on stable haemodialysis.
Data showed that a significantly higher proportion of patients in the Lokelma group (41.2%) met the primary endpoint and were classified as responders compared to patients in the placebo group (1.0%).
This marks the first label update for Lokelma in Europe following its EC approval in 2018 to treat adults with hyperkalaemia, and it follows a green light by the US Food and Drug Administration for the new dosing regimen last week.
By: Selina McKee
Source: Pharma Times
Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.
Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.
Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.